

Amendments to the Claims:

Please amend claim 13 and 14 as shown below in the List of Claims.

List of Claims:

1-12. Cancelled.

- 1 ~~13~~. (Currently amended) A method for assaying a test compound for its ability to alter the expression of the human amyloid precursor protein, comprising:
- a) preparing a vector for recombinantly expressing a peptide or protein in a eukaryotic cell, wherein said vector comprises:
 - i) a promoter which is active in said eukaryotic cell;
 - ii) a translation enhancer element consisting essentially of the nucleotide sequence of SEQ ID NO:1, wherein said element is 3' to said promoter;
 - iii) a DNA sequence encoding said peptide or protein, wherein said DNA sequence:
 - aa) lies 3' to said translation enhancer element;
 - bb) is operably linked to said promoter; and
 - cc) is non-homologous to said translation enhancer element;
 - b) measuring the expression of said ~~gene~~ peptide or protein in said vector in the absence of said test compound; and
 - c) comparing the expression determined in step b) with the expression of said ~~gene~~ peptide or protein in the presence of said test compound.
- 2 ~~14~~. (Currently amended) The method of claim ~~13~~¹, further comprising transforming a host cell with said vector prior to measuring the expression of said ~~gene~~ peptide or protein.
- 3 ~~15~~. (Previously presented) The method of claim ~~14~~¹, wherein said test compound comprises a nucleic acid sequence complementary to a region of SEQ ID NO:1 at least 10 base pairs in length.
- 4 ~~16~~. (Previously presented) The method of claim ~~15~~¹, wherein said test compound is an RNA targeting compound.

- ⁵11. (Previously presented) The method of claim ²14, wherein said host cell is an astrocyte or astrocytoma cell.
- ⁶18. (Previously presented) The method of any one of claims ¹⁻⁵~~13-17~~, wherein said assay is carried out in the presence of one or more cytokines.
- ⁷19. (Previously presented) The method of any one of claims ⁵~~13-17~~, wherein said assay is carried out in the presence of either interleukin-1 α or interleukin-1 β .
- ⁸20. (Previously presented) The method of any one of claim ¹⁻⁵~~13-17~~, wherein said method includes measuring mRNA levels of said protein or peptide.
- ⁹21. (Previously presented) The method of claim ⁸20, wherein said assay is carried out in the presence of one or more cytokines.
- ¹⁰22. (Previously presented) The method of claim ⁸20, wherein said assay is carried out in the presence of either interleukin-1 α or interleukin-1 β .